Original Research
Accepted on 05 Aug 2025
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in China
in Pharmacoepidemiology
- 131 views